Pharmaceuticals
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tiru...
2025-11-24 20:00
1881
Beyfortus® (nirsevimab) now available in Malaysia to protect all infants against RSV disease
* Beyfortus® (nirsevimab) is an available option designed to protect all infants – whether born full-term or pre-term, healthy or with underlying conditions – against respiratory syncytial virus (RSV), with proven high and sustained efficacy, a favourable safety profile, and real-world public h...
2025-11-24 16:55
1982
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced onNovember 20 that it has administered the f...
2025-11-24 15:11
1050
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an u...
2025-11-24 08:01
1705
GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
* Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology * Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea and HONG KONG, Nov. 24, 2025 /PRNewswire/ -- G...
2025-11-24 08:00
1606
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
PISCATAWAY, N.J., Nov. 22, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum London 2025 in the UK. This marks the Forum's second edition inEurope and the eighth consecutive G...
2025-11-22 20:28
2102
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
PISCATAWAY, N.J., Nov. 21, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum London 2025 in the UK. This marks the Forum's second edition inEurope and the eighth consecutive G...
2025-11-22 06:32
2387
Global Health Leaders Convene in Kuala Lumpur from 25-27 November for Malaysia International Healthcare Megatrends 2025
A Major Conference on Innovation, Digital Health and Sustainable Care Systems KUALA LUMPUR, Malaysia, Nov. 22, 2025 /PRNewswire/ -- Healthcare leaders, policymakers and innovators from around the world will convene inMalaysia next week for the Malaysia International Healthcare (MIH) Megatrends 20...
2025-11-22 02:05
3794
BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
* Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their partnership spanning over two years. * Demonstrating Robust Capabilities: Throughout the collaboration, all technology transfers and GMP manufact...
2025-11-21 21:00
1904
Hong Kong hosts landmark International Genomic Medicine Symposium
300 Industry Leaders Gather to Drive Medical Innovations and Showcase Hong Kong's Strengths HONG KONG, Nov. 21, 2025 /PRNewswire/ -- The International Genomic Medicine Symposium (Symposium), jointly organised by the Hong Kong Genome Institute (HKGI), Rare Diseases International (RDI), and The La...
2025-11-21 15:49
1188
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the official opening of Telix Manufacturing Solutions (TMS) inYokohama, Japan, the Company's first cyclotron facility in theAsia Pacific region (APAC...
2025-11-21 14:22
3360
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
* Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program * The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity ...
2025-11-21 13:46
1246
Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
* The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated Antigen (TAA) Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States, marking an important milestone in its global clinical dev...
2025-11-21 12:01
2022
HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases
* Company enters into new agreement with the Gates Foundation to identify novel drug leads targeting tuberculosis and malaria and new agents for non-hormonal contraception. CHENGDU, China, Nov. 20, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH...
2025-11-20 22:30
1164
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer
* The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. * The world's first gastric cancer perioperative regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting has met primary endpoints in its phase 3 cli...
2025-11-20 18:52
3676
WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Recognition in the CRDMO Industry
WuXi AppTec sets new benchmarks in strategic execution and technological
advancement, further strengthening its ability to support innovators worldwide
as they deliver breakthrough medicines for patients.
SAN ANTONIO, Nov. 20, 2025 /PRNewswire/ -- Frost & Sullivan
2025-11-20 10:00
934
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab) PET/CT[2] wo...
2025-11-20 03:00
1566
Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
BEIJING and LISBON, Portugal, Nov. 19, 2025 /PRNewswire/ -- At PEGS Europe
2025, one of the industry's premier gatherings for innovation in protein and
antibody engineering, Tsingke Biotech highlighted its latest acceleratedprotein
2025-11-19 22:17
1181
Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery
Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IN...
2025-11-19 20:08
1430
Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restric...
2025-11-19 08:00
3630
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 327 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
8613